• IGC Pharma posted a net loss attributable to common stockholders of $2.4 million, widening from $1.2 million a year earlier, while loss per share held at $0.02.
• Revenue edged down 3.94% to $317,000 from the prior-year quarter.
• R&D expenses climbed to $1.3 million from $997,000, driven by the progression of the Phase 2 CALMA trial for IGC-AD1.
• SG&A expenses rose to $1.2 million from $570,000, on the absence of a $700,000 credit recorded in the year-ago quarter tied to the conversion of accrued cash bonuses into performance-based compensation.
• The Phase 2 CALMA trial remained ongoing with a target enrollment of 146 patients, with patient enrollment reaching about 80% after March; CEO Ram Mukunda said the near-term focus remains on completing CALMA with disciplined capital allocation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.